Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IL-15-expressing chimeric antigen receptor T-cells (Shanxi Bethune Hospital)
- Development stage
- Unknown
- Lead developer
- Shanxi Bethune Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
IL-15-expressing chimeric antigen receptor T-cells (Shanxi Bethune Hospital) is an investigational autologous CAR-T cell therapy being developed for the treatment of relapsed or refractory hematological malignancies, including acute lymphocytic leukemia (ALL), non-Hodgkin lymphoma (NHL), and multiple myeloma. The therapy involves T cells genetically engineered to express a chimeric antigen receptor (CAR) alongside Interleukin-15 (IL-15). IL-15 is a potent cytokine that promotes the survival, expansion, and metabolic fitness of T cells and natural killer (NK) cells. By co-expressing IL-15, these CAR-T cells are designed to overcome common limitations such as poor persistence and exhaustion in the tumor microenvironment, potentially enhancing anti-tumor efficacy and long-term remission in patients with advanced blood cancers.
- Other names
- IL-15 co-expressing CAR-T cellsIL15 co-expressing CAR-T cellsIL 15 co-expressing CAR-T cellsNovel CAR-T combined expression of IL-15chimeric antigen receptor gene modified T cells
02
Targets
IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)
Beyond the preview
Go deeper on IL-15-expressing chimeric antigen receptor T-cells (Shanxi Bethune Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IL-15-expressing chimeric antigen receptor T-cells (Shanxi Bethune Hospital).